Access Restriction

Author Gu, Jianchun ♦ Zheng, Leizhen ♦ Wang, Yajie ♦ Zhu, Meiling ♦ Wang, Qin ♦ Li, Xiaoping
Source SpringerLink
Content type Text
Publisher Springer Netherlands
File Format PDF
Copyright Year ©2014
Language English
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword HER2 ♦ Human epidermal growth factor receptor ♦ Gastric cancer ♦ Prognosis ♦ Meta-analysis ♦ Cancer Research
Abstract The prognostic significance of HER2 expression in patients with gastric cancer remains controversial, partially due to the significant heterogeneity of the approaches and criteria used for HER2 assessment among different studies. We therefore conducted a meta-analysis enrolling only studies defining HER2 status by trastuzumab for gastric cancer (ToGA) criteria. Published studies investigating the association between HER2 expression and survival were identified. Only publications that defined HER2 expression using ToGA criteria were enrolled. Meta-analyses were performed by Revman 5.2. Pooled hazard ratio (HR) and its 95 % confidence interval (CI) were calculated to evaluate the risk of disease. A total of 11 studies were enrolled in meta-analyses. Pooled data of nine studies using univariate analysis showed that HER2 expression is not associated with overall survival (OS; pooled HR, 0.97; 95 % CI, 0.84–1.12; P = 0.63), which are maintained in six studies of multivariate analysis (pooled HR, 1.01; 95 % CI, 0.75–1.35; P = 0.95). The Q statistic test for nine studies of univariate analysis and for six studies of multivariate analysis showed no and low heterogeneity (I $^{2}$ = 22 % and P = 0.25; I $^{2}$ = 41 % and P = 0.13, respectively). Furthermore, pooled data of four studies without heterogeneity (I $^{2}$ = 0 %, P = 0.74) showed that HER2 expression were not associated with relapse-free survival as well, with a pooled HR of 1.08 (95 % CI, 0.84–1.37; P = 0.55) in patients with HER2 expression. In conclusion, this meta-analysis indicated that HER2 expression based on ToGA criteria is not related to the survival in patients with gastric cancer.
ISSN 10104283
Age Range 18 to 22 years ♦ above 22 year
Educational Use Research
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2014-02-21
Publisher Place Dordrecht
e-ISSN 14230380
Journal Tumor Biology
Volume Number 35
Issue Number 6
Page Count 7
Starting Page 5315
Ending Page 5321

Open content in new tab

   Open content in new tab
Source: SpringerLink